Preliminary summaries of the other 10 studies are reported here.
The EuroAction study was presented by David Wood from London, UK. This cluster randomized study assessed a strategy to improve adherence to evidence-based medicine in primary and secondary prevention of cardiovascular disease. A nurse-led multi-disciplinary prevention programme (intervention arm) was compared to usual care with respect to achieving preventive treatment goals as formulated in the European preventive cardiology guidelines. The patients' partners or direct relatives also participated in the study. The primary endpoints were the proportion of patients achieving the preventive treatment goals. Patients could enter from two sources. First, patients with chronic stable angina or acute coronary syndrome were recruited from hospitals. Second, patients at high risk for vascular events were recruited from general practices. Patients from the hospital followed a 16-week programme and those from general practices followed a 1-year programme. At the end of the respective programmes, the effect of the intervention was assessed. The data of 8657 patients and partners, recruited from 24 centres spread over eight European countries, were presented. Smoking cessation by patients from the hospital tended to be more frequent in the intervention arm than in the usual care arm (58 vs. 47%, P ¼ 0.06); a little over 70% of the patients from general practice stopped smoking in both arms. The dietary goals, especially regarding the consumption of fruits and vegetables, were achieved more often in the intervention group. With respect to physical activity, targets were reached twice as frequent in the intervention group: 50% compared with 20%. Among the partners, physical activity was positively influenced as well. The intervention led to more patients achieving an ideal waist circumference: 30% compared with 20% in the usual care arm, mainly accounted for by more male subjects achieving this treatment goal. Risk factors also were better managed in the nurse-led programme: blood pressure targets were more often reached, glycaemic control was better, and lipid levels more often improved. Finally, the use of cardio-protective drugs was improved. The hospital group with coronary artery disease (CAD) patients more frequently received antiplatelet therapy, statins, and beta-blockers. The high-risk patients from general practices more frequently received diuretics, angiotensin-converting enzyme-inhibitors (ACE-inhibitors), and statins. In conclusion, a nurse-led multi-disciplinary approach to cardiovascular risk intervention is associated with a higher proportion of patients reaching treatment targets, and a more optimized pharmacological treatment of coronary patients, and high-risk primary prevention patients.
In the double-blind international multi-centre ACCLAIM trial, presented by Guillermo Torre-Amione from Houston, USA, the effect of broad-spectrum immune-modulation therapy with the Celacade w system was compared with placebo (sham) in patients with chronic heart failure. Inflammatory cytokines and other mediators of inflammation are thought to contribute to the progression of heart failure. The Celacade system uses a 10 mL sample of autologous blood that is subjected to oxidative stress. Then, after intramuscular re-injection, the white blood cells undergo apoptosis, a process that is associated with anti-inflammatory responses. The main inclusion criteria were an ejection fraction of ,30% and heart failure New York Heart Association (NYHA) classes II-IV plus hospitalization for heart failure within the past 12 months (classes III and IV also eligible if ejection fraction of ,25% and no recent heart failure hospitalization). Moreover, patients should be on standard heart failure therapy. Patients were randomized to immune modulation therapy (n ¼ 1213) or sham treatment (n ¼ 1213). Subjects received treatment on days 1, 2, 14, 28, and every 28 days thereafter for minimally 22 weeks or until the end of the study. The baseline characteristics were well balanced, with 80% males, two-thirds of the patients in NYHA class III, a mean ejection fraction of 22%, and two-thirds of patients with ischaemic aetiology of heart failure. Baseline therapy was of high standard in both groups, with ACE-inhibitors and beta-blockers being used by 90% of the subjects. The combined primary endpoint of mortality and cardiovascular hospitalization was not significantly reduced in the immune modulation therapy group, compared with placebo (HR 0.92; 95% CI 0.80-1.05). All-cause mortality did not differ between immune modulation therapy and placebo, 10.6 and 9.7%, respectively (P ¼ 0.45). No increase in serious adverse events was observed. The subgroups of patients with NYHA class II and those without a history of myocardial infarction did benefit of immune modulation therapy. In conclusion, immune modulation therapy did not significantly reduce mortality or cardiovascular hospitalization. Much of the presentation focused on the two subgroups that did benefit of immune modulation therapy. However, randomized trials targeted on these subgroups are necessary to provide a definite answer on the value of immune modulation therapy in these patients.
The Home or Hospital in Heart failure study was presented by Andrea Mortara from Monza, Italy. Home telemonitoring may advance detection of clinical deterioration of heart failure patients leading to earlier adaptation of therapy, reducing mortality, and unplanned hospitalization for heart failure. Patients with chronic heart failure were randomly assigned to usual care, or to one of three groups with different home-based telemonitoring strategies. The first telemonitoring group received periodic telephone calls by dedicated nurses and had a 24 h answering machine at their disposal in case of problems. The second group received the same care as group 1 plus weekly monitoring of vital signs, which could be submitted to the hospital through an interactive voice response system. The third group received the same care as group 2 plus monthly 24 h continuous recordings of ECG, respiration, and activity with a Holter style recorder, applied by the patient self. After recording, the results were transmitted to the hospital by a modem. The control group consisted of 160 patients, and the telemonitoring groups included about 100 patients each. Italy, Poland, and UK participated in the study. Patients should meet the following criteria: heart failure NYHA classes II-IV, ejection fraction of ,40%, admission for heart failure within the past 12 months, an abnormal diastolic left ventricular function, and optimal medical therapy. Baseline characteristics were well balanced. Mean age was 60 years, 15% were female, aetiology of heart failure was mainly ischaemic, mean NYHA class was 2.4, and the mean left ventricular ejection fraction was 29%. Transmission of telemonitoring data was feasible: 81% of vital sign transmissions and 78% of the transmissions of the home cardio-respiratory recordings were practicable. The primary endpoint of hospitalization due to heart failure after 1 year was similar in the control group and in the three telemonitoring groups (16.3 vs. 16.9%, respectively), as was the combined endpoint of death and hospitalization (18.8 vs. 20.6%, respectively). In both groups, 6.3% of patients had been hospitalized twice or more. The results for the three individual telemonitoring groups were not shown. Interestingly, in Italy, the primary endpoint was reduced in the telemonitoring arm, whereas in Poland, it was increased, mainly due to increased numbers of patients being hospitalized twice or more. In conclusion, home telemonitoring in heart failure patients is feasible, and patient compliance to monitoring is high. However, the main clinical outcome of the trial is neutral.
The session ended with the presentation of two meta-analyses on the hot topic of late stent thrombosis with drug-eluting stents (DESs). Currently, the majority of stents implanted worldwide is a DES (55%), and its use is still steadily increasing. In some countries, even 90% of stents implanted are DESs. Although DESs spectacularly reduce the rate of the rather benign event of in-stent restenosis, in the past years, concern has been raised with respect to a possibly increased risk of stent thrombosis, a complication associated with high mortality. The following two meta-analyses address this important issue.
The first meta-analysis was presented by Edoardo Camenzind from Geneva, Switzerland and studied the risk of death and non-fatal myocardial infarction in the randomized controlled trials comparing sirolimus-(SESs) or paclitaxel-eluting stents (PESs) with bare-metal stents (BMSs). On the basis of the latest available follow-up data of four studies comparing SES with BMS, a significant increase in death or non-fatal Q-wave myocardial infarction was observed: 6.3 vs. 3.9%, respectively (P ¼ 0.03), consistent with a 38% relative increase after a maximum of 4 years of follow-up. For five studies that compared PES with BMS, no increased risk for the combined endpoint of death or infarction was observed after a maximum of 3 years of follow-up: 2.6 vs. 2.3%, respectively (P ¼ 0.68).
The second meta-analysis presented by Alain Nordmann from Basel, Switzerland compared SES or PES with BMS to evaluate its effect on total, cardiac, and non-cardiac death during long-term follow-up. Seventeen studies were included in the analysis. Overall mortality with DES during follow-up tended to be increased, compared with BMS. The odds ratios (ORs) after 1, 2, and 3 years were 0.94, 1.11, and 1.25, respectively (P ¼ ns). Cardiac death with the use of DES tended to be less in the first 2 years after implantation when compared with BMS (OR after 1 year 0.84 and after 2 years 0.73), but was identical after 3 years (OR 1.0). Non-cardiac death was increased for DES compared with BMS: OR 1.72 (CI 1.01-2.94) after 2 years and 1.45 (CI 0.93-2.25) after 3 years. The difference was driven by a significantly higher rate of non-cardiac mortality in SES-treated patients at these time points: ORs 2.74 (CI 1.22-6.13) and 2.04 (CI 1.00-4.15), respectively. PES also tended to lead to higher non-cardiac death rates, but less pronounced than SES.
Thus, overall mortality of DES tended to be higher than that of BMS. Death and re-infarction were significantly increased in patients who received an SES and tended to be increased in patients who received a PES. Unexpectedly, non-cardiac mortality was significantly increased in the SES-treated patients, but not in the PES-treated patients. The discussant Salim Yusuf from Hamilton, Canada urged for further research, especially long-term clinical follow-up for the occurrence of late stent thrombosis and non-cardiac mortality. As DESs do not reduce the risk of infarction or mortality, these should be used cautiously at least until these data are available.
The second Hotline session opened with the WAVE trial, presented by Sonia Anand from Hamilton, Canada. The WAVE trial was a randomized open-label study of aspirin alone vs. the combination of aspirin plus moderate intensity oral anticoagulation (INR 2-3) in patients with peripheral artery disease. As combination therapy has been shown to be beneficial in high-risk patients with recent myocardial infarction, the hypothesis was tested whether this would also be the case for peripheral artery disease. In addition, the assessment of bleeding risk was a major endpoint. Follow-up was performed every 3 months for 3 years. The major inclusion criteria were intermittent claudication with objective evidence, previous vascular reconstruction, or asymptomatic peripheral artery disease (ankle/brachial 28th European Congress of Cardiologyindex ,0.9 and/or carotid stenosis .50%). Patients with a high bleeding risk, indication for oral anticoagulation, and recent stroke were excluded. A run-in phase of 2-4 weeks during which patients used combination therapy was started by 2417 patients, of these 256 stopped, and 2161 patients were evenly randomized between the two treatment groups. In the combination therapy group, the mean INR achieved was 2.2, and 319 patients permanently discontinued study medication. In the aspirin group, 45 patients switched to the use of oral anticoagulation. Baseline characteristics were well balanced. Mean age was 64 years, onequarter of the patients was female, one-third smoked, almost half had CAD, and 15% had a history of stroke. The qualifying condition was arterial disease of the limbs in over 80% of the patients. Before enrolment, 99% of the subjects already used antiplatelet therapy. The first co-primary composite efficacy endpoint of cardiovascular death, myocardial infarction, and stroke was not reduced by combination therapy, compared with aspirin alone: 12.2 vs. 13.3%, respectively (P ¼ 0.49). The second co-primary endpoint, the first primary plus severe ischaemia, was not affected either: 15.9 vs. 17.4%, respectively (P ¼ 0.38). None of the components of the primary endpoint were reduced. However, life threatening bleedings were significantly increased by combination therapy, compared with aspirin: 4.0 vs. 1.2%, respectively (P , 0.001). Of these bleeds, 0.9 vs. 0.3% were fatal (P ¼ 0.051) and 1.3 vs. 0%, respectively, were intracranial (P ¼ ,0.001). In explanation of the lack of benefit of combination therapy, most likely, the thrombotic risk in this population was too low for the antithrombotic benefits to outweigh the increased risk of bleeding complications. In general, combination therapy cannot be recommended for patients with peripheral artery disease.
The RIVIERA study presented by Gilles Montalescot from Paris, France includes a registry of elective and primary percutaneous coronary interventions (PCIs) in patients not pretreated with anticoagulation. Current practice in PCI was characterized, and predictors of adverse clinical and angiographic outcomes were studied, with special attention for the use of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) in the cath lab. In 23 countries, 144 centres participated, including 7962 patients. Prior myocardial infarction was present in 31% prior coronary artery bypass grafting (CABG) in 5%, and prior PCI in 13%. Indications for PCI were stable CAD in 45%, non-ST-elevation acute coronary syndrome in 36%, ST-elevation myocardial infarction (STEMI) 12 h of symptom onset in 9%, STEMI .12 h of symptom onset in 11%, and other indications in 7%. In 11%, a radial approach was used. In 95% of patients, one or more stents were placed. Most patients received aspirin and clopidogrel, and 18% also received a glycoprotein (GP) IIb/IIIa inhibitor. Anticoagulation consisted of UFH alone in 36%, of LMWH alone in 58%, and of UFH plus LMWH or other anticoagulation in 6%. In-hospital clinical outcome was excellent: 0.3% mortality and 1.0% myocardial infarction. Major bleeding was seen in 0.3%. The most important independent predictor of increased risk of death or myocardial infarction was PCI for all indications other than stable CAD. Factors associated with lower risk of death or infarction were radial approach, pre-treatment with a thienopyridine, and the use of LMWH compared with UFH. Strong predictors of mortality were PCI of the left main trunk and female gender. Important predictors of bleeding included the use of GP IIb/IIIa inhibitors, the combined use of UFH and LMWH, and PCI of bypass grafts. Radial access reduced the bleeding risk. The most frequent angiographic complications were coronary dissection (3.7%), no reflow (2.0%), and thrombus (1.9%). The strongest risk factors for angiographic complications were STEMI and plain balloon angioplasty. In conclusion, rates of mortality, infarction, and bleeding were strikingly low in this registry. Important predictors of the outcome events were PCI of the left main trunk and of bypass grafts. With respect to bleeding, it appears important to avoid the combined use of UFH and LMWH and to use GP IIb/IIIa blockers only selectively. Radial access seems safer with respect to bleeding complications. However, these results should be interpreted cautiously as they are not based on randomized data.
Patrick Serruys from Rotterdam, the Netherlands, presented the 6-month angiographic, intravascular ultrasound (IVUS) and the clinical results of the SPIRIT-2 trial. In this international, multi-centre randomized, single-blind noninferiority trial, the new everolimus-eluting stent (EES) was compared with the PES. Everolimus, like sirolimus, interferes in the G1 phase of the cell cycle. Three hundred patients were randomized in a 3:1 fashion to EES or PES, respectively. In all patients angiography was performed at baseline and after 180 days, in half of the patients combined with IVUS. Patients were eligible if they had a de novo target lesion, without thrombus, length 28 mm, vessel diameter between 2.5 and 4.25 mm, stenosis severity 50 and ,100%, and TIMI flow grade 1. Baseline characteristics were equally distributed. The mean age was 62 years, 25% was diabetic, lesions were type III in 13%, and mean lesion length was 13 mm. Dual lesions treated were 17 and 18% in the EES and PES groups, respectively, and procedural success was 99 and 97% respectively. In both arms, diameter stenosis was reduced from 60% at baseline to 13% postprocedural. Pre-procedural minimal luminal diameter was 1.06 and 1.14 mm in the EES and PES arms, respectively, with a reference vessel diameter of 2.70 and 2.82 mm respectively; post-procedural minimal luminal diameter was 2.49 vs. 2.62 mm, respectively (P , 0.05). The primary endpoint of late loss of luminal diameter at 180 days was significantly reduced by the EES compared with the PES: 0.11 (SD 0.27) vs. 0.39 mm (SD 0.39), P , 0.0001, meeting the criteria for superiority. Nevertheless, binary restenosis rate was similar between EES and PES arms. After 6 months, IVUS analysis showed that in EES, neointimal volume and volume obstruction were 70% lower than that in PES. Both arms had one patient with late stent thrombosis. The composite of cardiac death, myocardial infarction, and target lesion revascularization tended to be lower in the EES arm: 2.7 vs. 6.5%. Thus, angiographic and IVUS outcomes of EES are superior to PES. The risk of major cardiac events was low. However, in the light of the current discussion on the risk of late stent thrombosis associated with DESs, large phase 3 randomized trials with long-term clinical follow-up are awaited.
The randomized VIAMI trial was presented by Gerrit Veen from Amsterdam, the Netherlands. Patients with viable myocardium in an infarction area are at increased risk of ischaemic events when compared with those without viability. VIAMI investigated whether shortly after acute myocardial infarction, patients with viability in the
